News & Events


Hardman & Co Healthcare Index

The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments over the long term. 2018 was a difficult year; however, the index still outperformed its comparative London indices, falling 10.0% to 393.2, compared with -13.0& and -18.2% for the Allshare index and the AIM index, respectively.

In the media MiFID II Monitor

MiFID II one year on – Mike Sheen of Investment Week references Hardman & Co analysis

Mike Sheen explains ‘The requirement to ‘unbundle’ research costs from the rest of sell-side services is thought to have taken a toll on research coverage and therefore liquidity as a result of reduced trading volumes.’  Asset Mangers have turned to cutting the number of brokers in order to reduce cost and this has led to a reduction in stock liquidity.


The QCA Board Brief: What the changing investment research landscape means for public companies

Hardman & Co provide an understanding as to what companies can do in response to the changing research environment.

Events News

Hardman & Co analyst, Steve Clapham, discusses the rise of ‘Accounting Fraud’ at Mello London

This week Hardman & Co analyst, Steve Clapham, made a fantastic contribution to Mello London; a unique Investor conference offering access to 50+ high-quality growth companies, outstanding keynote investment industry speakers from whom to learn, and the opportunity to network with fellow private investors.

Events News

‘Disruption, Disruption, Disruption’: Hardman & Co analyst Nigel Hawkins presents at Mello London

Yesterday, Hardman & Co analyst Nigel Hawkins presented on the topic of market disruption to a full house at Mello London.

In the media Video

VIDEO: Paul Mylchreest on the fundamentals driving demand for Lithium

Our mining analyst, Paul Mylchreest updates London South East with the change in demand for Lithium, in part driven by the growth of electric vehicles.

In the media MiFID II Monitor

MIFID II dampening liquidity and cutting research

Liquidity – a key measure of investors’ ability to buy and sell shares without significantly moving the price – has fallen 16% on the London Stock Exchange Main Market since MiFID II came into force, according to Hardman & Co analysis.

In the media MiFID II Monitor

Financial Times features new Hardman & Co findings in the Lex column

Lex today feature new Hardman & Co findings which highlight both the receding liquidity in mid-cap AIM stocks and the reduction in research coverage.

In the media MiFID II Monitor

Liquidity of mid-cap AIM stocks diminishing post MiFID II- Investment Week

Mike Sheen of Investment Week features Hardman & Co MiFID II Monitor data highlight drop in liquidity and research coverage.

Twitter icon Created with Sketch.

Twitter latest